Invalidity dossier
US 9827239
Oligomer-opioid agonist conjugates
Current assignee: Nektar Therapeutics
Added 9/21/2026, 12:39:41 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US 9,827,239 B2
Title: Oligomer-opioid agonist conjugates
Source: https://patents.google.com/patent/US9827239/en
Assignee: Nektar Therapeutics (original assignee per the supplied record; current assignee listed as Nektar Therapeutics). Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley.
Key dates (as listed): Priority date 2007-03-12; filing date 2016-11-02; publication/grant date 2017-11-28; legal status "Active"; anticipated expiration 2028-03-12. The record also notes priority claims from PCT/US2008/003353 and PCT/US2010/042792, and later applications claiming priority to this one (e.g., US15/791,951; US16/165,364; US16/682,906).
Field and purpose: The patent concerns oligomer-opioid agonist conjugates and related compounds, compositions, and methods of making them (indicated by the listed compounds, synthetic schemes, and "Chemical compound" entries). The recurring structural depiction contains a morphinan-type core bearing substituents R1–R5, consistent with an opioid agonist scaffold, and the prior-art keywords are "mPEG," "compound," "oligomer," "peg," and "conjugates" — indicating conjugation of opioid agonist moieties to PEG/oligomer (e.g., mPEG) groups.
Plain-language scope (as evidenced by the excerpt): The text depicts conjugates in which an opioid-type (morphinan) molecule is linked through positions such as the 3-hydroxy/3-alkoxy position and/or the 6-position to short oligomer/PEG chains (for example, methoxyethoxy and mPEG-containing groups), including exemplary compounds (e.g., mPEG-substituted morphinan structures) and reaction schemes for their preparation. The disclosure appears to extend to compounds, conjugates, and preparation methods rather than only a single species.
Not established by the excerpt: No complete claim set, specification text, claim language, or explicit therapeutic indication is provided in the excerpted source; therefore claim scope, embodiments, dosages, indications, and assay results cannot be stated. The excerpt does not establish litigation, ownership transfers beyond the assignment entries shown, validity, or prior-art effect, and no such analysis is offered here. Details such as the full recited Markush definitions for R1–R5 are not available from this excerpt.
Generated 10/1/2026, 10:01:04 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 9827239. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.